“We believe in a world with universal access to genomic information. Genapsys is uniquely positioned to fulfill this vision by providing an affordable and scalable sequencing ecosystem to patients, physicians and researchers worldwide.”
— Jason Myers, CEO
Jason brings over 20 years of experience in the genomics industry. Prior to Genapsys, he was co-founder and CEO of ArcherDX, continuing his track record of successful technology development and enterprise value creation. Before that, Jason led platform and sequencing application development for Ion Torrent™ where his leadership contributed to its acquisition by Life Technologies.
Britton brings comprehensive finance experience in emerging growth companies and multinational organizations. He previously worked as SVP of Finance at ArcherDX, a genomic analysis company, and later Invitae, when it acquired ArcherDX. Before that, Britton held a diverse range of corporate finance roles with increasing responsibility at AstraZeneca, Genentech, and Royal Dutch Shell.
Mary spent more than 20 years leading organizations in federal healthcare. Her experience includes resource management, logistics, IT, and diagnostics services in US and international markets. Her most recent role was Vice President for Global Diagnostic Strategy at Invitae. Prior to that, she led Operations, Supply Chain, and Public Policy teams at ArcherDX and Invitae.
Dana has far-reaching experience in strategic business and legal counsel, government investigations, and law enforcement. Most recently she was a partner at Cooley LLP, specializing in corporate litigation, advising CEOs and Boards on business strategy, regulatory compliance, and risk mitigation. Dana was also a Special Agent in the U.S. Air Force Office of Special Investigations.
Ryan has extensive experience in creating and delivering innovative NGS assays for research and diagnostics. Prior to Genapsys, he served in a series of roles with increasing responsibility at ArcherDX, culminating as EVP of Research and Development. He led development of a personalized cancer monitoring platform, multiple clinical trial assays and research use only products.